Phreesia (PHR) to Release Quarterly Earnings on Monday

Phreesia (NYSE:PHR) will announce its earnings results after the market closes on Monday, December 9th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Phreesia has set its FY 2025 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The business had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Phreesia Price Performance

PHR opened at $21.03 on Monday. Phreesia has a 1 year low of $14.55 and a 1 year high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The company’s 50 day simple moving average is $20.43 and its 200 day simple moving average is $21.84. The stock has a market capitalization of $1.21 billion, a PE ratio of -11.68 and a beta of 0.94.

Wall Street Analyst Weigh In

PHR has been the subject of a number of research analyst reports. Canaccord Genuity Group restated a “buy” rating and set a $34.00 price objective on shares of Phreesia in a report on Thursday, September 5th. JPMorgan Chase & Co. upped their price target on Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, September 9th. Truist Financial lifted their price objective on Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, September 6th. DA Davidson reissued a “buy” rating and set a $32.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Finally, JMP Securities restated a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a report on Thursday, September 5th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.42.

Insider Activity

In other news, insider Yvonne Hui sold 2,791 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.92, for a total transaction of $58,387.72. Following the completion of the sale, the insider now owns 27,228 shares of the company’s stock, valued at approximately $569,609.76. This trade represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Allison C. Hoffman sold 1,212 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total transaction of $25,488.36. Following the transaction, the general counsel now owns 119,791 shares in the company, valued at $2,519,204.73. This trade represents a 1.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,997 shares of company stock worth $667,943. 5.80% of the stock is currently owned by company insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.